Scientific Sessions 2024  /  Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?  /  Incretin Analogues for Addressing Multisystem Morbidity
Logo

American Heart Association

  159
  0

Final ID:

Incretin Analogues for Addressing Multisystem Morbidity

  • Neuen, Brendon  ( George Institute for Global Health , Newtown , New South Wales , Australia )
  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
    • Author Disclosures:
    Brendon Neuen: DO have relevant financial relationships ; Consultant:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Menarini:Expected (by end of conference) ; Consultant:Travere Therapeutics:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Boehringer and Ingelheim:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:Alexion:Active (exists now) | Chiadi Ndumele: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Effects of Tirzepatide on the Clinical and Symptom Burden of Patients with Heart Failure and a Preserved Ejection Fraction, Results from the SUMMIT Trial

Zile Michael

Discussant: SUMMIT

Lewis Eldrin

More abstracts from these authors:
Cardiovascular Risk Prediction with the Kidney Failure Risk Equation Among Patients with Chronic Kidney Disease: Insights from CRIC

Correa Simon, Beldhuis Iris, Neuen Brendon, Vaduganathan Muthiah, Wilson F. Perry, Mc Causland Finnian

The Expanding Therapeutic Options for Diabetic Kidney Disease: A Clinical Trial Overview

Neuen Brendon, Agarwal Rajiv, Rangaswami Janani

You have to be authorized to contact abstract author. Please, Login
Not Available